Ipamorelin and CJC-1295 turn up in the same research conversations constantly, and it is easy to assume they do the same job. They do not. One is a ghrelin receptor agonist; the other is a growth hormone releasing hormone analog. That distinction — receptor target, half-life, selectivity, and research application — is exactly what this guide walks through, side by side, so researchers can match the right compound to the right study design. Everything below stays within a research-use-only (RUO) framing; nothing here describes human dosing or self-administration. By the end, you will understand how Ipamorelin and CJC-1295 differ mechanistically, what CJC-1295 with DAC changes about that comparison, and how to evaluate purity and sourcing before selecting either compound for a research protocol.
Featured Products
What Is Ipamorelin?
Ipamorelin is a pentapeptide — a chain of just five amino acids — classified as a growth hormone releasing peptide (GHRP) and a selective ghrelin receptor agonist. It binds the GHS-R1a receptor, the same receptor the hormone ghrelin activates naturally, and triggers a sharp, pulsatile release of growth hormone from the pituitary gland.
Compared to earlier-generation GHRPs such as GHRP-6 and GHRP-2, Ipamorelin research points to a narrower, more targeted effect. It shows minimal stimulation of cortisol, prolactin, or appetite-related signaling at the receptor level, which is why it is frequently chosen when a study needs to isolate growth-hormone-specific activity without those secondary variables.
What Is CJC-1295?
CJC-1295 is a synthetic analog of growth hormone releasing hormone (GHRH), the hypothalamic hormone that signals the pituitary gland to release growth hormone. Built on a modified 29-30 amino acid GHRH fragment, CJC-1295 resists the rapid enzymatic breakdown that limits natural GHRH, giving researchers a more stable tool for studying the GHRH receptor pathway.
Two versions matter here: CJC-1295 with DAC (drug affinity complex) and CJC-1295 without DAC, sometimes labeled Mod GRF 1-29. DAC binds the peptide to circulating albumin, extending its research half-life from minutes to multiple days — a modification that changes almost every practical comparison to Ipamorelin, covered in detail below.
Ipamorelin vs CJC-1295: Mechanism of Action Compared
The core distinction is receptor target. Ipamorelin activates the ghrelin receptor; CJC-1295 activates the GHRH receptor. These are two independent signaling systems in the hypothalamic-pituitary axis that both terminate in growth hormone release, but through different upstream triggers.
Key Takeaway Ipamorelin and CJC-1295 are not two versions of the same tool. One mimics ghrelin; the other mimics GHRH. Comparing them means comparing two separate receptor pathways, not two potency levels of a single mechanism. |
Because the pathways are independent, published pharmacology on GHRH analogs and ghrelin mimetics frequently treats them as complementary rather than competing tools — which is also why they show up together in combination research, even though this guide focuses on comparing them individually.
Ipamorelin vs CJC-1295: Full Comparison Table
The table below summarizes the practical differences researchers weigh when selecting between the two compounds.
Factor | Ipamorelin | CJC-1295 |
|---|---|---|
Peptide class | GHRP / selective ghrelin receptor agonist | GHRH analog |
Amino acid length | 5 (pentapeptide) | ~29-30 (modified GHRH fragment) |
Receptor target | Ghrelin receptor (GHS-R1a) | GHRH receptor |
Half-life (research) | Short — roughly 2 hours | Minutes (no DAC) to days (with DAC) |
Release pattern | Pulsatile, short-acting | Pulsatile (no DAC) or sustained (DAC) |
Off-target effects studied | Minimal cortisol/prolactin activity | GHRH-specific, minimal ghrelin crossover |
Best suited for | Isolating ghrelin-receptor-specific effects | Isolating GHRH-receptor-specific effects |
Neither compound is categorically "better" — they answer different research questions. The right choice depends on which receptor pathway a study is designed to isolate.
CJC-1295 DAC vs. No DAC: Why It Changes the Comparison
- CJC-1295 with DAC: multi-day half-life, sustained GHRH receptor occupancy — a very different kinetic profile than Ipamorelin's short pulses.
- CJC-1295 without DAC (Mod GRF 1-29): minutes-long half-life, sharp pulsatile signal — closer to Ipamorelin's pulsatile behavior, though still acting on a separate receptor.
Researchers directly comparing half-life or pulsatility between the two compounds need to specify which CJC-1295 variant is in play; "CJC-1295" alone is not a single kinetic profile.
Selectivity: Ipamorelin vs. GHRP-6 and GHRP-2
Selectivity is one of Ipamorelin's most cited research attributes. Compared to GHRP-6 and GHRP-2 — older ghrelin receptor agonists — Ipamorelin research describes a cleaner activation profile with less stimulation of cortisol, prolactin, and appetite-related pathways. CJC-1295 does not compete in this comparison directly, since it targets an entirely different receptor family, but the selectivity discussion is often raised alongside CJC-1295 in broader GHRH-vs-GHRP literature reviews.
Cost, Purity, and Vial Considerations
Cost per milligram varies by supplier, vial concentration, and — for CJC-1295 — whether the DAC modification is included, since DAC formulation typically adds to manufacturing cost. Comparing price alone is misleading; purity percentage and verification method matter just as much for research validity.
High-Performance Liquid Chromatography (HPLC) remains the standard purity verification method for both compounds, ideally paired with mass spectrometry to confirm molecular identity. A trustworthy supplier provides a batch-specific Certificate of Analysis (COA) matched to the lot number on the vial for both Ipamorelin and CJC-1295 — not a generic report reused across production runs.
Common Mistake Comparing Ipamorelin and CJC-1295 purely on advertised price per vial without checking whether the COA is batch-matched and third-party verified. A cheaper vial with unverifiable purity is not actually the better research value. |
How to Evaluate a Supplier for Either Compound
- Confirm the supplier provides a current, batch-matched COA for the specific compound and lot you are ordering.
- Check whether purity testing is performed by an independent third-party lab, not solely in-house.
- Verify the product page and packaging clearly state research-use-only (RUO) status and disclaimers.
- Look for domestic US sourcing and cold-chain shipping practices that protect peptide stability in transit.
- Test documentation responsiveness — a supplier slow to produce a COA on request is a warning sign regardless of which peptide you are sourcing.
Practical Handling Notes for Research Use
These notes describe general laboratory handling practices for research purposes only and are not instructions for human use.
- Both Ipamorelin and CJC-1295 are typically supplied lyophilized and should be stored frozen and shielded from light prior to reconstitution.
- Bacteriostatic water is the standard reconstitution diluent referenced in peptide research literature for both compounds.
- Once reconstituted, refrigeration and minimizing repeated freeze-thaw cycles are the variables most consistently linked to preserved stability for either peptide.
- Always default to the specific stability window and handling guidance a supplier or institutional protocol provides rather than a generic timeframe.
Common Mistakes When Comparing Ipamorelin and CJC-1295
- Treating the two as interchangeable because they both influence growth hormone release, despite acting on entirely different receptors.
- Comparing "CJC-1295" generically without specifying whether the DAC or no-DAC version is meant — a distinction that changes the entire half-life comparison.
- Judging cost without checking purity percentage or COA verification for either compound.
- Assuming higher selectivity for Ipamorelin within its GHRP class means it is automatically "stronger" than CJC-1295 — the two are not on a shared potency scale.
KEY TAKEAWAYS
- Ipamorelin is a selective ghrelin receptor agonist (GHRP); CJC-1295 is a growth hormone releasing hormone (GHRH) analog — different receptor targets entirely.
- Ipamorelin's half-life is short and consistently pulsatile; CJC-1295's half-life depends entirely on whether it includes the DAC modification.
- Ipamorelin is noted for high selectivity within its GHRP class, with minimal off-target cortisol/prolactin activity in research models.
- Purity verification (third-party HPLC, batch-matched COA) matters equally for both compounds regardless of price.
- All content in this guide is framed strictly for research-use-only (RUO) purposes and does not describe human dosing or administration.
Frequently Asked Questions
What is the main difference between Ipamorelin and CJC-1295?
Ipamorelin is a selective ghrelin receptor agonist (a GHRP) that mimics the hormone ghrelin, while CJC-1295 is a growth hormone releasing hormone (GHRH) analog. They bind different receptors on the pituitary gland, so they trigger growth hormone release through two separate mechanisms rather than being interchangeable versions of the same compound.
Is Ipamorelin more selective than CJC-1295?
Selectivity is measured differently for each class. Within its own class, Ipamorelin is considered the most receptor-selective GHRP, with research indicating minimal off-target stimulation of cortisol or prolactin compared to older GHRPs like GHRP-6. CJC-1295 is selective for the GHRH receptor within its class of GHRH analogs. Comparing them head-to-head is less about which is "more selective" overall and more about which pathway a study needs to isolate.
Does CJC-1295 have a longer half-life than Ipamorelin?
It depends on the CJC-1295 variant. CJC-1295 with DAC (drug affinity complex) has a research half-life measured in days due to albumin binding, which is substantially longer than Ipamorelin's short half-life of roughly two hours. CJC-1295 without DAC, however, clears in minutes — closer to Ipamorelin's pulsatile profile.
What is CJC-1295 with DAC and how does it compare to Ipamorelin?
CJC-1295 with DAC is the long-acting version of the GHRH analog, chemically modified to bind serum albumin and remain active for days rather than minutes. Ipamorelin, by contrast, is inherently short-acting regardless of formulation, since its ghrelin-receptor mechanism is designed around a sharp, pulsatile signal rather than sustained receptor occupancy.
How does Ipamorelin's mechanism differ from CJC-1295's?
Ipamorelin binds the ghrelin receptor (GHS-R1a) and triggers a rapid, pulsatile growth hormone release, similar to the body's natural ghrelin signaling. CJC-1295 binds the GHRH receptor and extends or amplifies the hypothalamic-pituitary GHRH signal. The two use entirely separate receptor systems that happen to converge on the same downstream hormone.
What does research-use-only mean for these peptides?
Research-use-only (RUO) labeling means the compound is manufactured, sold, and intended strictly for laboratory and in-vitro research by qualified personnel — not for human consumption or therapeutic use. Reputable suppliers state RUO status clearly on packaging, product pages, and documentation.
How is peptide purity verified for Ipamorelin and CJC-1295?
Purity is verified primarily through High-Performance Liquid Chromatography (HPLC), which separates and quantifies the compound against a reference standard, often paired with mass spectrometry to confirm molecular weight and identity. A reliable supplier provides a batch-specific Certificate of Analysis (COA) for every lot.
What is a Certificate of Analysis (COA)?
A COA is a lab report tied to a specific production batch that documents purity percentage, testing method, and molecular confirmation. Researchers should be able to match the COA's lot number to the number printed on their vial rather than relying on a generic, undated report.
How should Ipamorelin and CJC-1295 be stored?
Lyophilized (freeze-dried) peptides are generally stored frozen and shielded from light before reconstitution. Once reconstituted with bacteriostatic water, refrigeration and minimizing freeze-thaw cycles are the consistent variables supplier documentation points to for preserving stability.
How long does reconstituted Ipamorelin or CJC-1295 remain stable?
Stability windows vary by peptide, buffer, and storage conditions, so researchers should follow the specific guidance their supplier or institutional protocol provides rather than a generic timeframe. Cold storage and avoiding repeated freeze-thaw cycles are the factors most consistently linked to stability.
Are Ipamorelin and CJC-1295 third-party tested?
Reputable suppliers send production batches to an independent laboratory for third-party HPLC verification rather than relying solely on in-house testing, which removes the conflict of interest inherent in a supplier grading its own product.
Is Ipamorelin cheaper than CJC-1295, or vice versa?
Pricing varies by supplier, vial concentration, and whether CJC-1295 includes the DAC modification (which typically costs more to manufacture). Researchers comparing cost per study should look at price per milligram alongside purity percentage rather than sticker price alone.
What is the amino acid sequence difference between Ipamorelin and CJC-1295?
Ipamorelin is a pentapeptide — five amino acids — giving it a comparatively small molecular weight. CJC-1295 is a much longer chain, built on a modified 29-30 amino acid GHRH fragment, which is part of why the two compounds behave so differently in terms of stability and receptor interaction.
Can Ipamorelin be studied without CJC-1295, and vice versa?
Yes. Both compounds have an established single-peptide research literature. Studying either alone isolates that specific receptor pathway, which is useful when a research question is specific to ghrelin-receptor or GHRH-receptor behavior rather than their combined or comparative effect.
How do researchers decide between Ipamorelin and CJC-1295 for a study?
The decision generally comes down to the research question. Studies targeting ghrelin-receptor-specific effects, short pulsatile signaling, or minimal off-target hormone activity tend to use Ipamorelin. Studies targeting sustained GHRH receptor occupancy, prolonged exposure windows, or GHRH-specific pharmacology tend to use CJC-1295 — often with DAC.
